Tryp Therapeutics is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs.
Learn more
Cohesive, commercially-oriented management team and board with significant overlapping large pharma and emerging pharma experience
Near-term Phase 2 ready oncology asset – leveraging extensive body of clinical research and familiarity of key opinion leaders (“KOL”) to efficiently expedite development, both in terms of cost and time
Developing psilocybin-based therapeutics for neuropsychiatric indications and will seek regulatory approval pursuant U.S. FDA regulatory pathway
Developing therapeutics for diseases with no effective first-line treatments, no competition, translates to pricing power with insurance companies
Developing product candidates through Phase 2 clinical development, then monetize through transaction with big biotech / large pharma
Leveraging existing clinical data, accelerated clinical development due to smaller, shorter, open-label clinical trials
